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VIV is a useful alternative in selected patients who are at
high risk for undergoing an open surgical procedure. Case
selection is of paramount importance and should be dis-
cussed during an MDT. Patients with small bioprosthetic
valves may be treated with VIV if the risk of conventional
surgery is prohibitive. It is important to be familiar with
the details of the in situ bioprostheses, including type,
size, fluoroscopic appearance, and method of implantation,
to have a successful outcome. Early results reveal improve-
ment in hemodynamics and amelioration of symptoms, but
longer follow-up with more patients is needed.A
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DrMathew R. Williams (New York, NY). I would like to thank
the American Association for Thoracic Surgery for the honor of
discussing this paper and thank you, Dr Bapat, for sending the pa-
per to me ahead of time. I had the pleasure of discussing a some-
what similar paper last year at this meeting, looking at VIV, and it
is nice as a U.S. physician to now be discussing it with actually
having experience with this procedure now that we have an ap-
proved system.
I will say that doing a transcatheter VIV is actually one of my
favorite procedures and I think it is really remarkable how well
these patients do. With this procedure in particular, it gives us
the advantages of the transcatheter procedure, a less invasive pro-
cedure with better recovery, but I think we also avoid some of the
bad things that have been affiliated with transcatheter valves—
namely, the paravalvular leak rate should probably be almost noth-
ing in most cases, and in theory we might have a lower stroke rate,
but we certainly don’t know that.
I am very impressed with your experience. It is still based on 23
patients, so I certainly don’t have anything to be critical of your
presentation, but would rather ask you some questions related to
how you conduct your clinical practice.
The first question is, I am wondering whether, given that this is
such a great procedure for a degenerated bioprosthesis, have you
changed your clinical practice in patients who are having surgical
aortic valve replacements? Namely, are you putting tissue valves in
younger patients? And if so, given what you discussed with the
gradients, are you perhaps more aggressive about a root enlarge-
ment in somebody who you wouldn’t normally if you might be op-
erating on an 80-year-old who you don’t expect to be operating on
again?
The second question is about the approach. I amwondering why
you did so many of these TA. I do understand that in some of thediovascular Surgery c Volume 144, Number 6 1379
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Dfirst reports of this procedure it was recommended that it be done
TA for better control, but I will be honest, I haven’t really under-
stood that, and our approach has been just to do the procedures. If
they have good access, we will do a TF; if they don’t, we will cer-
tainly do a TA.
And then the final question, which you alluded to a little bit, in
the largest experience that was presented at the Transcatheter
Valve Therapy meeting this year, there was a surprisingly high in-
cidence, or a higher incidence than I expected—it’s still a low in-
cidence—of coronary occlusion, which was most prominent with
stentless valves and, in particular, actually, the Mitroflow valve,
and I think 3 of your patients had the Mitroflow valve. I am won-
dering if you could comment on how you are addressing that po-
tential fatal complication.
Dr Bapat. Thank you, Dr Williams, for your questions. My
practice hasn’t changed, but patients are well informed now that
we are doing a VIV procedure, and patients come to us saying
they want a bioprosthetic valve because there is a good chance
that in 10 to 15 years they will have a keyhole treatment by which
we will take care of it. I give the choice to the patients regarding
what kind of valve they are going to have, depending on their life-
style and aversion to warfarin.
Yes, if I do a bioprosthetic valve in younger patients, my aim is
to put a larger bioprosthesis. Having performed TAVI as well as an
open aortic valve practice, that is going to be very important, be-
cause these patients are going to present at an age of maybe 75
or 80, and if I can at least put a 26 size Sapien valve, or whichever
device is available at that time, it will definitely add 10 more years
in each patient.
Your second question: Why TA? Absolutely. It was initially
thought that it gives you better tactile feel, better control while
you are inflating it slowly. Also if you remember with the Retro-
Flex 1 system, which lacked a nosecone crossing the valve, there
were some catastrophic events such as leaflet tears, or sometimes
the valve got stuck on the stent. And I think that is the only reason
why units like ours have gone ahead and have just done TA. But we
are changing with the availability of the NovaFlex system. And I
completely agree with you that it should be taken the same way
we treat the native aortic valve; the access should be determined
by that.
And your last question about coronary obstruction, we are very
cautious, and, as I mentioned in my presentation, with designs like
Mitroflow, designs like Trifecta, but I think all the designs, espe-
cially in small valves, these patients tend to have small sinuses
of Valsalva, and then we can do a BAV to check if there is1380 The Journal of Thoracic and Cardiovascular Sura coronary obstruction. If I am correct, there are only 3 cases re-
ported in the literature currently—2 with Mitroflow and 1 with
Mosaic—that have led to coronary obstruction. However, I think
in real life probably the incidence is much higher than that.
Dr Jahanzaib Idrees (Cleveland, Ohio). I have 1 question re-
garding younger patients in whom it would be more reasonable
to place a mechanical valve. There are patients who are hesitant
to get a mechanical valve and they don’t want to take Coumadin.
So I am interested in knowing your perspective.Would you be con-
fident in placing a bioprosthetic valve in that patient based on what
you explained your results with so that maybe later on, if the valve
wears off, you can do a VIV procedure? What would be your ap-
proach to convince that patient? Will you tell him to get a mechan-
ical valve or would you tell him that a bioprosthetic valve may still
be an option given the feasibility of a VIV procedure?What would
be your approach in that regard?
Dr Bapat. As I said before, the approach hasn’t changed, be-
cause this should still be the result for high-risk patients. We
don’t know how long these valves are going to last. As I showed
you before, circularity is very important, and in TAVI procedures
currently, you can’t control circularity in these patients. So I think
options to the patients still remain the same. If they are young, they
should decide whether they need to have a mechanical or biopros-
thetic valve. I don’t make the choice for them.
Dr Ludwig Karl von Segesser (Lausanne, Switzerland). Con-
gratulations for a nice series. You have not been very specific about
the gradients in the smaller sizes of your valves. Could you specify
about the 21 mm and the 19 mm especially?
Dr Bapat. Certainly. I think the residual gradients in all those
patients were much, much higher. So we had a drop-off average
gradient from 30 mm Hg to 9 mm Hg, but in these patients we
had residual gradients, so mean gradients of at least 20 mm Hg.
However, we undertook them as the last option, and the patients
had very good symptomatic relief.
Dr Adrian Jeremy Levine (Stoke-on-Trent, UK). Very impres-
sive work. Do you do balloon valvuloplasty for all valves of your
late series? We started, like you, the first 1 or 2, not doing it, but
now we have gone back and we balloon valvuloplasty all of
ours. What about you?
Dr Bapat. We have gone the other way around. In fact, in our
first case we did a BAV. I think the difference is because we do
the TA. You don’t need to do a BAV. And the procedure is very
short, only one pacing episode, and, again, I think doing
a BAV—unless you are worried about coronary obstruction—I
think there is no need to do a BAV.gery c December 2012
